Therapy Areas: Devices
Qiagen expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
2 November 2021 - - German sample and assay technologies provider Qiagen (NYSE: QGEN) (Frankfurt Prime Standard: QIA) has launched the newly CE-marked QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2, the company said.

Qiagen's new Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test is a powerful diagnostic tool in the COVID-19 pandemic, especially in influenza like illness or "flu" seasons.

It leverages the easy-to-use QIAstat-Dx modular cartridge-based system to deliver fast results that require no additional sample preparation.

The polymerase chain reaction (RT-PCR) multiplex test detects and differentiates between influenza A and B, respiratory syncytial virus and SARS-CoV-2 infections in about an hour a vital capability in the fight against the COVID-19 pandemic.

The viruses produce similar respiratory symptoms, making it challenging to clinicians to diagnose exactly which one a patient is suffering from to make the right treatment decisions.

Recent publications in the Journal of Antimicrobial Chemotherapy have highlighted the value of syndromic testing for clinicians and laboratorians.

The publications in the supplement highlight various considerations such as how to maximize impact of infectious diseases syndromic panels, collaboration between laboratories and antimicrobial stewardship programs, utilizing syndromic panels outside of the central laboratory and what factors impact clinical decisions to utilize syndromic verses low-plex PCR.

Qiagen currently offers the QIAstat-Dx Respiratory+ test and the QIAstat-Dx Gastrointestinal test. It also has a strong pipeline of additional tests in development, including one for Meningitis.

As of H1 2021, Qiagen has over 2400 QIAstat-Dx instruments in the market worldwide.

In March, Qiagen announced additional digital diagnostics and connectivity features for QIAstat-Dx through QIAsphere.

The QIAstat-Dx system was introduced in Europe in 2018 after receiving the region's CE marking and in the United States in mid-2019 after being cleared by the Food and Drug Administration.

The easy-to-use device enables fast and cost-effective syndromic testing with novel Sample to Insight workflows.

The system streamlines molecular testing from beginning to end. A technician simply loads a clinical sample for example, on a swab into a single-use QIAstat-Dx cartridge and places it in the analyzer.

With Qiagen chemistries for sample processing and analysis built in, the QIAstat-Dx instrument delivers results in about one hour.

Qiagen N.V., a Netherlands-based holding company, is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.

Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.

Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows.

Qiagen provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R and D and industrial applications, primarily forensics).

As of June 30, 2021, Qiagen employed approximately 5,900 people in over 35 locations worldwide.
Login
Username:

Password: